Credit Suisse has issued an update note on SYR today.
Valuation has increased from $4.90 to $5.60.
Lots of interesting comments about the Vanadium - all very positive. Here is one of them that I liked:
"In our view, the extension of the feasibility study is unlikely to delay the start or ramp up timing. Additional capital cost is unlikely to require additional equity in our view. Management indicate that there is strong customer interest in off-take agreements providing sound lender credit."
I will try and find a link that I can post.
- Forums
- ASX - By Stock
- SYR
- credit suisse upgrade
credit suisse upgrade
Featured News
Add SYR (ASX) to my watchlist
(20min delay)
|
|||||
Last
24.0¢ |
Change
-0.005(2.04%) |
Mkt cap ! $248.3M |
Open | High | Low | Value | Volume |
24.5¢ | 25.0¢ | 24.0¢ | $1.021M | 4.204M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
30 | 1014192 | 24.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
24.5¢ | 190056 | 6 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
29 | 981839 | 0.240 |
16 | 1056383 | 0.235 |
22 | 1467153 | 0.230 |
11 | 1202988 | 0.225 |
12 | 942418 | 0.220 |
Price($) | Vol. | No. |
---|---|---|
0.245 | 190056 | 6 |
0.250 | 104868 | 5 |
0.255 | 191000 | 4 |
0.260 | 57466 | 3 |
0.265 | 190000 | 4 |
Last trade - 16.10pm 13/11/2024 (20 minute delay) ? |
Featured News
SYR (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Michael Thurn, CEO & MD
Michael Thurn
CEO & MD
SPONSORED BY The Market Online